We are live on ! Find out more
OMGA

Omega Therapeutics, Inc. Common Stock

Delisted

OMGA was delisted on the 24th of February, 2025.

48 hedge funds and large institutions have $389M invested in Omega Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

69% more capital invested

Capital invested by funds: $231M → $389M (+$158M)

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

9% more funds holding

Funds holding: 4448 (+4)

0.27% less ownership

Funds ownership: 89.04%88.77% (-0.27%)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

8% less call options, than puts

Call options by funds: $314K | Put options by funds: $343K

Holders
48
Holders Change
+4
Holders Change %
+9.09%
% of All Funds
0.77%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
6
Increased
12
Reduced
13
Closed
2
Calls
$314K
Puts
$343K
Net Calls
-$29K
Net Calls Change
-$24K

OMGA Hedge Fund Activity: Q4 2022 in Review

48 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q4 2022, worth a combined $389M — up 69% from $231M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new OMGA positions and 2 closed out — a net gain of 4 holders — while 12 added to existing stakes and 13 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $375K. The largest seller was BlackRock, cutting an estimated $467K.

  • 48 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q4 2022, up from 44 in Q3 2022.
  • Funds reported $389M of Omega Therapeutics, Inc. Common Stock stock for Q4 2022, up 69% quarter-over-quarter.
  • 6 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q4 2022 and 2 closed out, a net change of +4 holders.
  • The largest Omega Therapeutics, Inc. Common Stock buyer in Q4 2022 was Susquehanna International Group, an estimated $375K added.
  • The largest Omega Therapeutics, Inc. Common Stock seller in Q4 2022 was BlackRock, an estimated $467K sold.

Based on aggregated 13F filings for Q4 2022.